Quantitative diffusion weighted MR imaging of microcapillary perfusion and tissue diffusivity as biomarkers of response of renal cell carcinoma to treatment with sunitinib or Pazopanib (DIRECTS)

Trial Profile

Quantitative diffusion weighted MR imaging of microcapillary perfusion and tissue diffusivity as biomarkers of response of renal cell carcinoma to treatment with sunitinib or Pazopanib (DIRECTS)

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Pazopanib (Primary) ; Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms DIRECTS
  • Most Recent Events

    • 05 Dec 2015 Planned End Date changed from 31 Dec 2015 to 31 Jan 2016 as reported by United Kingdom Clinical Research Network.
    • 19 Jul 2015 Accrual to date is 33% according to United Kingdom Clinical Research Network.
    • 19 Jul 2015 Planned End Date changed from 10 Oct 2014 to 31 Dec 2015, according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top